Share Price and Basic Stock Data
Last Updated: January 8, 2026, 6:17 pm
| PEG Ratio | -9.21 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Morepen Laboratories Ltd operates in the pharmaceuticals sector, focusing on manufacturing and marketing a range of pharmaceutical products. The company reported a market capitalization of ₹2,274 Cr and a current share price of ₹41.5. Over the years, Morepen has shown a consistent revenue growth trajectory; for instance, its total sales rose from ₹1,188 Cr in March 2021 to ₹1,690 Cr in March 2024. In the trailing twelve months, sales stood at ₹1,755 Cr, reflecting a robust operational performance. Quarterly sales data indicates a positive trend, with sales increasing from ₹403 Cr in September 2022 to ₹422 Cr in September 2023, and projected at ₹466 Cr for March 2025. This growth can be attributed to strategic initiatives and a focus on expanding its product portfolio, which has helped the company capture a larger market share in a competitive environment.
Profitability and Efficiency Metrics
Morepen Laboratories’ profitability metrics indicate a mixed performance. The operating profit margin (OPM) stood at 7% as of September 2023, with fluctuations observed in the quarterly figures, peaking at 11% in December 2023. The company recorded a net profit of ₹99 Cr, translating to an earnings per share (EPS) of ₹2.20 for March 2025. The return on equity (ROE) was reported at 11.8%, slightly below the sector average, which typically ranges around 15-20% for established pharmaceutical companies. Efficiency ratios, such as the cash conversion cycle (CCC) of 45 days, suggest that Morepen manages its working capital effectively, although there is room for improvement in inventory turnover, which was reported at 6.60 times for March 2025. Overall, while the company shows profitability, its margins are under pressure compared to sector leaders.
Balance Sheet Strength and Financial Ratios
The balance sheet of Morepen Laboratories reflects a stable financial position, with total assets recorded at ₹1,778 Cr and total borrowings of ₹158 Cr, resulting in a low debt-to-equity ratio of 0.06, indicating minimal leverage. The company’s reserves have grown significantly, from ₹651 Cr in March 2023 to ₹1,087 Cr in September 2025, enhancing its financial flexibility for future investments. The interest coverage ratio (ICR) stood impressively at 23.07x, showcasing the company’s strong ability to meet its interest obligations. Additionally, the current ratio of 2.32x indicates a solid liquidity position, well above the industry norm of 1.5x. However, the price-to-book value (P/BV) ratio of 2.27x reflects a premium valuation compared to the sector, suggesting that the stock may be overvalued relative to its book value.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Morepen Laboratories reveals a diverse ownership structure. Promoters hold 35.66% of the shares, a slight decline from previous quarters, indicating potential dilution of control. Foreign institutional investors (FIIs) accounted for 1.62%, while domestic institutional investors (DIIs) held 1.49%, reflecting modest institutional interest. The public holds a substantial 61.22%, which suggests strong retail participation. The number of shareholders has increased to 4,61,853 as of September 2025, indicating growing investor confidence. However, the decline in promoter stake may raise concerns regarding long-term commitment, especially among conservative investors. Overall, the mix of shareholding suggests a balanced approach to governance and potential for future growth through increased institutional interest.
Outlook, Risks, and Final Insight
Looking ahead, Morepen Laboratories is well-positioned to capitalize on the growing pharmaceutical market, driven by its expanding product portfolio and robust sales growth. However, the company faces risks, including margin pressures due to rising raw material costs and competition from larger pharmaceutical firms. Additionally, fluctuations in regulatory policies can impact operational efficiency. Strengths include a solid balance sheet with low debt levels and a strong interest coverage ratio, which provide a buffer against economic uncertainties. If the company can leverage its reserves effectively for expansion and innovation, it may enhance profitability further. Conversely, failure to address margin pressures could hinder growth. In light of these factors, maintaining operational efficiency while navigating market challenges will be crucial for Morepen’s sustained success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 210/84.3 | 27.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,543 Cr. | 417 | 479/192 | 94.1 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.2 Cr. | 47.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 57.1 Cr. | 39.0 | 40.0/17.0 | 136 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,630.92 Cr | 1,148.75 | 53.05 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 403 | 348 | 364 | 401 | 422 | 445 | 423 | 455 | 438 | 453 | 466 | 425 | 412 |
| Expenses | 374 | 328 | 348 | 375 | 388 | 394 | 375 | 404 | 394 | 417 | 424 | 401 | 381 |
| Operating Profit | 29 | 21 | 16 | 26 | 34 | 51 | 48 | 52 | 44 | 36 | 42 | 24 | 31 |
| OPM % | 7% | 6% | 4% | 7% | 8% | 11% | 11% | 11% | 10% | 8% | 9% | 6% | 7% |
| Other Income | 1 | 1 | 3 | 2 | 3 | 4 | 4 | 3 | 5 | 5 | 5 | 4 | 30 |
| Interest | 0 | 1 | 1 | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 5 | 4 | 4 |
| Depreciation | 7 | 7 | 7 | 8 | 8 | 8 | 10 | 6 | 2 | 5 | 16 | 9 | 11 |
| Profit before tax | 22 | 14 | 11 | 21 | 29 | 44 | 42 | 48 | 46 | 35 | 26 | 16 | 46 |
| Tax % | 29% | 36% | 26% | 29% | 26% | 27% | 32% | 25% | 24% | 24% | 21% | 26% | 10% |
| Net Profit | 16 | 9 | 8 | 15 | 21 | 32 | 29 | 36 | 35 | 27 | 20 | 11 | 41 |
| EPS in Rs | 0.31 | 0.18 | 0.16 | 0.29 | 0.42 | 0.63 | 0.55 | 0.71 | 0.64 | 0.49 | 0.37 | 0.20 | 0.75 |
Last Updated: December 29, 2025, 10:35 pm
Below is a detailed analysis of the quarterly data for Morepen Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 412.00 Cr.. The value appears to be declining and may need further review. It has decreased from 425.00 Cr. (Jun 2025) to 412.00 Cr., marking a decrease of 13.00 Cr..
- For Expenses, as of Sep 2025, the value is 381.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 401.00 Cr. (Jun 2025) to 381.00 Cr., marking a decrease of 20.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 31.00 Cr.. The value appears strong and on an upward trend. It has increased from 24.00 Cr. (Jun 2025) to 31.00 Cr., marking an increase of 7.00 Cr..
- For OPM %, as of Sep 2025, the value is 7.00%. The value appears strong and on an upward trend. It has increased from 6.00% (Jun 2025) to 7.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 30.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Jun 2025) to 30.00 Cr., marking an increase of 26.00 Cr..
- For Interest, as of Sep 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 4.00 Cr..
- For Depreciation, as of Sep 2025, the value is 11.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9.00 Cr. (Jun 2025) to 11.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 46.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Jun 2025) to 46.00 Cr., marking an increase of 30.00 Cr..
- For Tax %, as of Sep 2025, the value is 10.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Jun 2025) to 10.00%, marking a decrease of 16.00%.
- For Net Profit, as of Sep 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Jun 2025) to 41.00 Cr., marking an increase of 30.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.75. The value appears strong and on an upward trend. It has increased from 0.20 (Jun 2025) to 0.75, marking an increase of 0.55.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:57 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 367 | 401 | 485 | 595 | 607 | 769 | 853 | 1,188 | 1,547 | 1,418 | 1,690 | 1,812 | 1,755 |
| Expenses | 318 | 352 | 424 | 534 | 542 | 701 | 785 | 1,070 | 1,410 | 1,338 | 1,532 | 1,638 | 1,622 |
| Operating Profit | 49 | 48 | 62 | 61 | 65 | 68 | 69 | 119 | 137 | 80 | 159 | 174 | 133 |
| OPM % | 13% | 12% | 13% | 10% | 11% | 9% | 8% | 10% | 9% | 6% | 9% | 10% | 8% |
| Other Income | 4 | 1 | -3 | 4 | 4 | 4 | 9 | 12 | 10 | 6 | 14 | 18 | 45 |
| Interest | 10 | 9 | 10 | 8 | 4 | 2 | 2 | 2 | -7 | 2 | 4 | 8 | 14 |
| Depreciation | 46 | 39 | 35 | 34 | 34 | 40 | 37 | 30 | 28 | 28 | 33 | 29 | 42 |
| Profit before tax | -3 | 2 | 13 | 24 | 30 | 29 | 39 | 99 | 127 | 56 | 135 | 155 | 122 |
| Tax % | 0% | 6% | -1% | 0% | 0% | 1% | 14% | 1% | 20% | 31% | 29% | 24% | |
| Net Profit | -3 | 2 | 13 | 24 | 30 | 29 | 34 | 97 | 102 | 39 | 97 | 118 | 99 |
| EPS in Rs | -0.06 | 0.05 | 0.28 | 0.53 | 0.66 | 0.64 | 0.75 | 2.16 | 2.13 | 0.76 | 1.88 | 2.15 | 1.81 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 9% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 166.67% | 550.00% | 84.62% | 25.00% | -3.33% | 17.24% | 185.29% | 5.15% | -61.76% | 148.72% | 21.65% |
| Change in YoY Net Profit Growth (%) | 0.00% | 383.33% | -465.38% | -59.62% | -28.33% | 20.57% | 168.05% | -180.14% | -66.92% | 210.48% | -127.07% |
Morepen Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: January 7, 2026, 4:05 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 96 | 102 | 102 | 110 | 110 |
| Reserves | 88 | 78 | 91 | 106 | 136 | 163 | 194 | 335 | 483 | 651 | 745 | 1,047 | 1,087 |
| Borrowings | 209 | 201 | 187 | 169 | 134 | 132 | 133 | 17 | 19 | 25 | 29 | 105 | 158 |
| Other Liabilities | 103 | 121 | 156 | 173 | 226 | 230 | 246 | 416 | 473 | 332 | 417 | 517 | 381 |
| Total Liabilities | 490 | 489 | 524 | 538 | 586 | 615 | 663 | 858 | 1,070 | 1,110 | 1,293 | 1,778 | 1,736 |
| Fixed Assets | 368 | 322 | 297 | 272 | 264 | 236 | 216 | 225 | 252 | 267 | 307 | 489 | 471 |
| CWIP | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 2 | 14 | 17 | 24 | 28 | 26 |
| Investments | -0 | -0 | -0 | -0 | 0 | 0 | 1 | 1 | -0 | -0 | 1 | 85 | 136 |
| Other Assets | 121 | 167 | 227 | 266 | 321 | 379 | 446 | 631 | 804 | 827 | 960 | 1,176 | 1,104 |
| Total Assets | 490 | 489 | 524 | 538 | 586 | 615 | 663 | 858 | 1,070 | 1,110 | 1,293 | 1,778 | 1,736 |
Below is a detailed analysis of the balance sheet data for Morepen Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 110.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 110.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,087.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,047.00 Cr. (Mar 2025) to 1,087.00 Cr., marking an increase of 40.00 Cr..
- For Borrowings, as of Sep 2025, the value is 158.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 105.00 Cr. (Mar 2025) to 158.00 Cr., marking an increase of 53.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 381.00 Cr.. The value appears to be improving (decreasing). It has decreased from 517.00 Cr. (Mar 2025) to 381.00 Cr., marking a decrease of 136.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,736.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,778.00 Cr. (Mar 2025) to 1,736.00 Cr., marking a decrease of 42.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 471.00 Cr.. The value appears to be declining and may need further review. It has decreased from 489.00 Cr. (Mar 2025) to 471.00 Cr., marking a decrease of 18.00 Cr..
- For CWIP, as of Sep 2025, the value is 26.00 Cr.. The value appears to be declining and may need further review. It has decreased from 28.00 Cr. (Mar 2025) to 26.00 Cr., marking a decrease of 2.00 Cr..
- For Investments, as of Sep 2025, the value is 136.00 Cr.. The value appears strong and on an upward trend. It has increased from 85.00 Cr. (Mar 2025) to 136.00 Cr., marking an increase of 51.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,104.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,176.00 Cr. (Mar 2025) to 1,104.00 Cr., marking a decrease of 72.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,736.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,778.00 Cr. (Mar 2025) to 1,736.00 Cr., marking a decrease of 42.00 Cr..
Notably, the Reserves (1,087.00 Cr.) exceed the Borrowings (158.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -160.00 | -153.00 | -125.00 | -108.00 | -69.00 | -64.00 | -64.00 | 102.00 | 118.00 | 55.00 | 130.00 | 69.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 42 | 51 | 66 | 57 | 73 | 64 | 59 | 56 | 59 | 68 | 70 | 65 |
| Inventory Days | 56 | 55 | 51 | 65 | 76 | 69 | 91 | 82 | 96 | 87 | 85 | 94 |
| Days Payable | 116 | 126 | 140 | 125 | 173 | 124 | 113 | 98 | 90 | 87 | 101 | 114 |
| Cash Conversion Cycle | -17 | -20 | -23 | -3 | -24 | 9 | 37 | 40 | 65 | 69 | 54 | 45 |
| Working Capital Days | -21 | -20 | -10 | -86 | -62 | -34 | -8 | 17 | 55 | 98 | 94 | 107 |
| ROCE % | 1% | 3% | 8% | 9% | 9% | 8% | 10% | 23% | 23% | 8% | 17% | 15% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal BSE Healthcare ETF | 4,401 | 0.16 | 0.02 | 4,401 | 2025-04-22 16:00:16 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 2.20 | 1.88 | 0.77 | 2.26 | 2.16 |
| Diluted EPS (Rs.) | 2.20 | 1.88 | 0.77 | 1.96 | 2.16 |
| Cash EPS (Rs.) | 2.68 | 2.54 | 1.30 | 2.71 | 2.83 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 21.10 | 16.58 | 14.72 | 12.10 | 9.43 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 21.10 | 16.58 | 14.72 | 12.10 | 9.43 |
| Revenue From Operations / Share (Rs.) | 33.06 | 33.07 | 27.73 | 32.37 | 26.41 |
| PBDIT / Share (Rs.) | 3.51 | 3.38 | 1.68 | 3.08 | 2.90 |
| PBIT / Share (Rs.) | 2.98 | 2.72 | 1.13 | 2.50 | 2.23 |
| PBT / Share (Rs.) | 2.83 | 2.65 | 1.09 | 2.65 | 2.19 |
| Net Profit / Share (Rs.) | 2.15 | 1.89 | 0.75 | 2.13 | 2.16 |
| NP After MI And SOA / Share (Rs.) | 2.15 | 1.88 | 0.75 | 2.13 | 2.16 |
| PBDIT Margin (%) | 10.62 | 10.21 | 6.04 | 9.50 | 10.99 |
| PBIT Margin (%) | 9.02 | 8.23 | 4.07 | 7.71 | 8.44 |
| PBT Margin (%) | 8.56 | 8.01 | 3.93 | 8.19 | 8.29 |
| Net Profit Margin (%) | 6.51 | 5.71 | 2.72 | 6.57 | 8.17 |
| NP After MI And SOA Margin (%) | 6.51 | 5.68 | 2.72 | 6.57 | 8.17 |
| Return on Networth / Equity (%) | 10.20 | 11.34 | 5.13 | 17.57 | 22.85 |
| Return on Capital Employeed (%) | 12.79 | 15.61 | 7.31 | 19.44 | 22.07 |
| Return On Assets (%) | 6.63 | 7.43 | 3.48 | 9.50 | 11.31 |
| Long Term Debt / Equity (X) | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.06 | 0.03 | 0.03 | 0.03 | 0.03 |
| Asset Turnover Ratio (%) | 1.18 | 1.41 | 1.30 | 1.60 | 1.47 |
| Current Ratio (X) | 2.32 | 2.21 | 2.35 | 1.61 | 1.30 |
| Quick Ratio (X) | 1.72 | 1.59 | 1.64 | 1.00 | 0.87 |
| Inventory Turnover Ratio (X) | 6.60 | 3.70 | 3.10 | 3.53 | 4.01 |
| Interest Coverage Ratio (X) | 23.07 | 46.52 | 43.25 | -19.96 | 73.02 |
| Interest Coverage Ratio (Post Tax) (X) | 15.15 | 27.04 | 20.53 | -12.81 | 55.29 |
| Enterprise Value (Cr.) | 2682.56 | 2126.72 | 1280.99 | 1720.86 | 1393.88 |
| EV / Net Operating Revenue (X) | 1.48 | 1.26 | 0.90 | 1.11 | 1.17 |
| EV / EBITDA (X) | 13.94 | 12.32 | 14.95 | 11.71 | 10.67 |
| MarketCap / Net Operating Revenue (X) | 1.45 | 1.27 | 0.92 | 1.13 | 1.22 |
| Price / BV (X) | 2.27 | 2.54 | 1.74 | 3.02 | 3.40 |
| Price / Net Operating Revenue (X) | 1.45 | 1.27 | 0.92 | 1.13 | 1.22 |
| EarningsYield | 0.04 | 0.04 | 0.02 | 0.05 | 0.06 |
After reviewing the key financial ratios for Morepen Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.20. This value is below the healthy minimum of 5. It has increased from 1.88 (Mar 24) to 2.20, marking an increase of 0.32.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.20. This value is below the healthy minimum of 5. It has increased from 1.88 (Mar 24) to 2.20, marking an increase of 0.32.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.68. This value is below the healthy minimum of 3. It has increased from 2.54 (Mar 24) to 2.68, marking an increase of 0.14.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 21.10. It has increased from 16.58 (Mar 24) to 21.10, marking an increase of 4.52.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 21.10. It has increased from 16.58 (Mar 24) to 21.10, marking an increase of 4.52.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 33.06. It has decreased from 33.07 (Mar 24) to 33.06, marking a decrease of 0.01.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.51. This value is within the healthy range. It has increased from 3.38 (Mar 24) to 3.51, marking an increase of 0.13.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.98. This value is within the healthy range. It has increased from 2.72 (Mar 24) to 2.98, marking an increase of 0.26.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.83. This value is within the healthy range. It has increased from 2.65 (Mar 24) to 2.83, marking an increase of 0.18.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.15. This value is within the healthy range. It has increased from 1.89 (Mar 24) to 2.15, marking an increase of 0.26.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 2.15. This value is within the healthy range. It has increased from 1.88 (Mar 24) to 2.15, marking an increase of 0.27.
- For PBDIT Margin (%), as of Mar 25, the value is 10.62. This value is within the healthy range. It has increased from 10.21 (Mar 24) to 10.62, marking an increase of 0.41.
- For PBIT Margin (%), as of Mar 25, the value is 9.02. This value is below the healthy minimum of 10. It has increased from 8.23 (Mar 24) to 9.02, marking an increase of 0.79.
- For PBT Margin (%), as of Mar 25, the value is 8.56. This value is below the healthy minimum of 10. It has increased from 8.01 (Mar 24) to 8.56, marking an increase of 0.55.
- For Net Profit Margin (%), as of Mar 25, the value is 6.51. This value is within the healthy range. It has increased from 5.71 (Mar 24) to 6.51, marking an increase of 0.80.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.51. This value is below the healthy minimum of 8. It has increased from 5.68 (Mar 24) to 6.51, marking an increase of 0.83.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.20. This value is below the healthy minimum of 15. It has decreased from 11.34 (Mar 24) to 10.20, marking a decrease of 1.14.
- For Return on Capital Employeed (%), as of Mar 25, the value is 12.79. This value is within the healthy range. It has decreased from 15.61 (Mar 24) to 12.79, marking a decrease of 2.82.
- For Return On Assets (%), as of Mar 25, the value is 6.63. This value is within the healthy range. It has decreased from 7.43 (Mar 24) to 6.63, marking a decrease of 0.80.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.02, marking an increase of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has increased from 0.03 (Mar 24) to 0.06, marking an increase of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.18. It has decreased from 1.41 (Mar 24) to 1.18, marking a decrease of 0.23.
- For Current Ratio (X), as of Mar 25, the value is 2.32. This value is within the healthy range. It has increased from 2.21 (Mar 24) to 2.32, marking an increase of 0.11.
- For Quick Ratio (X), as of Mar 25, the value is 1.72. This value is within the healthy range. It has increased from 1.59 (Mar 24) to 1.72, marking an increase of 0.13.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.60. This value is within the healthy range. It has increased from 3.70 (Mar 24) to 6.60, marking an increase of 2.90.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 23.07. This value is within the healthy range. It has decreased from 46.52 (Mar 24) to 23.07, marking a decrease of 23.45.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 15.15. This value is within the healthy range. It has decreased from 27.04 (Mar 24) to 15.15, marking a decrease of 11.89.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,682.56. It has increased from 2,126.72 (Mar 24) to 2,682.56, marking an increase of 555.84.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.48. This value is within the healthy range. It has increased from 1.26 (Mar 24) to 1.48, marking an increase of 0.22.
- For EV / EBITDA (X), as of Mar 25, the value is 13.94. This value is within the healthy range. It has increased from 12.32 (Mar 24) to 13.94, marking an increase of 1.62.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.45. This value is within the healthy range. It has increased from 1.27 (Mar 24) to 1.45, marking an increase of 0.18.
- For Price / BV (X), as of Mar 25, the value is 2.27. This value is within the healthy range. It has decreased from 2.54 (Mar 24) to 2.27, marking a decrease of 0.27.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.45. This value is within the healthy range. It has increased from 1.27 (Mar 24) to 1.45, marking an increase of 0.18.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Morepen Laboratories Ltd:
- Net Profit Margin: 6.51%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 12.79% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.2% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 15.15
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.72
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 29.5 (Industry average Stock P/E: 53.05)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.51%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Morepen Village, Solan District Himachal Pradesh 173205 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sushil Suri | Chairman & Managing Director |
| Mr. Sanjay Suri | Whole Time Director |
| Mr. Praveen Kumar Dutt | Independent Director |
| Dr.(Mrs.) Savita | Independent Director |
| Mr. Ranjit Khattar | Independent Director |
| Mr. Sharad Jain | Independent Director |
FAQ
What is the intrinsic value of Morepen Laboratories Ltd?
Morepen Laboratories Ltd's intrinsic value (as of 08 January 2026) is ₹61.01 which is 50.27% higher the current market price of ₹40.60, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹2,227 Cr. market cap, FY2025-2026 high/low of ₹74.5/38.4, reserves of ₹1,087 Cr, and liabilities of ₹1,736 Cr.
What is the Market Cap of Morepen Laboratories Ltd?
The Market Cap of Morepen Laboratories Ltd is 2,227 Cr..
What is the current Stock Price of Morepen Laboratories Ltd as on 08 January 2026?
The current stock price of Morepen Laboratories Ltd as on 08 January 2026 is ₹40.6.
What is the High / Low of Morepen Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Morepen Laboratories Ltd stocks is ₹74.5/38.4.
What is the Stock P/E of Morepen Laboratories Ltd?
The Stock P/E of Morepen Laboratories Ltd is 29.5.
What is the Book Value of Morepen Laboratories Ltd?
The Book Value of Morepen Laboratories Ltd is 21.8.
What is the Dividend Yield of Morepen Laboratories Ltd?
The Dividend Yield of Morepen Laboratories Ltd is 0.49 %.
What is the ROCE of Morepen Laboratories Ltd?
The ROCE of Morepen Laboratories Ltd is 15.1 %.
What is the ROE of Morepen Laboratories Ltd?
The ROE of Morepen Laboratories Ltd is 11.8 %.
What is the Face Value of Morepen Laboratories Ltd?
The Face Value of Morepen Laboratories Ltd is 2.00.